Vanda Pharmaceuticals (NASDAQ: VNDA) fell as much as 9% today after the FDA rejected the company’s experimental therapy, tradipitant. The therapy is aimed at treating gastroparesis, a stomach paralysis-related medical condition. The FDA has asked Vanda Pharmaceuticals to conduct further studies before resubmitting its application. However, VNDA isn’t holding back…
S&P 500 has already rallied well over 20% this year but Brian Belski, the chief investment strategist of BMO…
American stocks had a strong performance this week as the Federal Reserve embarked on an interest rate cutting cycle…
Cintas (CTAS) stock price has done well in the past decades, outperforming the S&P 500 index and most companies.…
Tesla (TSLA) and Nvidia (NVDA) stocks have done well in the past few days as American equities bounced back.…
Archer Aviation (ACHR) and Lilium (LILM) are two of the most popular electric vertical takeoff and landing (EVTOL) or…
Zimbabwe’s stock market is soaring, but it’s not for the usual reasons. Investors are flocking to equities as a…
Burberry Group (LON: BRBY) share price has been in a strong freefall this year as concerns about its growth…
HSBC (LON: HSBA) share price has risen for two consecutive weeks as investors focus on the actions by central…